Has Gian Rossi received payments from drug or device companies?

Yes. Drug and device makers reported $52,282 in general payments to Gian Rossi across 158 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gian Rossi did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gian Rossi come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gian Rossi

Neurology with Special Qualifications in Child Neurology · Lakeland, FLNPI 1497142178

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $44,588 of the $52,282 with a category attached, or 85.3%. Acadia Pharmaceuticals Inc accounts for 95.8% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $34,429, more than ten times the $15 reported in 2019.

$52,282in general payments, 2019–2025

Across 158 payments — averaging $330.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Acadia Pharmaceuticals Inc$50K
Livanova USA, Inc.$615
UCB, Inc.$568
Jazz Pharmaceuticals Inc.$177
Immedica Pharma US, Inc.$170
Eisai Inc.$131
plus $528 from 11 others

What the payments were for

Consulting fees$2,6005%
Speaking & faculty fees$44,58885%
Travel & lodging$2,3374%
Food & beverage$2,7405%
Education$170%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Acadia Pharmaceuticals Inc	102	$50,092
Livanova USA, Inc.	4	$615
UCB, Inc.	19	$568
Jazz Pharmaceuticals Inc.	7	$177
Immedica Pharma US, Inc.	2	$170
Eisai Inc.	3	$131
Zogenix Inc.	1	$125
Neurelis, Inc.	5	$102
Otter Pharmaceuticals, LLC	2	$73
Greenwich Biosciences, Inc.	3	$49
Cycle Pharmaceuticals Inc	2	$48
Azurity Pharmaceuticals, Inc.	2	$43
Aquestive Therapeutics, Inc.	2	$26
Catalyst Pharmaceuticals, Inc.	1	$17
Biocodex, Inc.	1	$16
Supernus Pharmaceuticals, Inc.	1	$16
Travere Therapeutics, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$52,282 in reported general payments places this provider in the 85th percentile of 137 neurology with special qualifications in child neurology providers in Florida.

See all neurology with special qualifications in child neurology providers in Florida →

Other neurology with special qualifications in child neurology in Lakeland

Paul WinnerWest Palm Beach$624K
Omer Abdul HamidOrlando$283K
Natalie GillsonFort Myers$250K
Trevor ResnickMiami$230K
Migvis MonduyMiami$188K
Elza VasconcellosMiami$170K
Ronald DavisWinter Park$154K
Ian MillerMiami$104K
Michael HammerSaint Petersburg$100K
Matt LallasMiami$88K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →